SCHEMBL378278

SCHEMBL378278

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)N2CCN(c3ccc(F)cc3)CC2)CC1)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
TACR1 P25103 1/20 0.47
NPY1R P25929 1/20 0.47
SLC6A4 P31645 1/20 0.47
PANK3 Q9H999 1/20 0.46
AKR1C3 P42330 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ATM Q13315 2/20 0.45
GLA P06280 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 1/20 0.44
TSHR P16473 2/20 0.43
ALOX15 P16050 2/20 0.43
ALDH1A1 P00352 1/20 0.43
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379204 0.98 NPSR1 (0.50) NPSR1TACR1NPY1RSLC6A4PANK3
SCHEMBL7908737 0.95 PANK3 (0.48) NPSR1TACR1NPY1RSLC6A4PANK3
SCHEMBL397969 0.91 ATM (0.55) NPY1RAKR1C3ATMKMT2APOLB
SCHEMBL13092501 0.89 ATM (0.48) NPSR1NPY1RSLC6A4AKR1C3ATM
SCHEMBL13092555 0.88 CCR1 (0.48) NPY1RSLC6A4AKR1C3ATMKMT2A
SCHEMBL7909141 0.87 KIT (0.44) NPSR1TACR1PANK3AKR1C3KDM4E
SCHEMBL13092493 0.87 MAPT (0.48) PANK3KDM4EATMKMT2ATSHR
SCHEMBL378812 0.85 NPSR1 (0.50) NPSR1TACR1AKR1C3KDM4EATM
SCHEMBL13092512 0.85 PIN1 (0.47) PANK3ATMKMT2ATSHRALOX15
SCHEMBL378735 0.85 NPY1R (0.52) TACR1NPY1RSLC6A4KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 NPSR1 13/4885TACR1 19/4885NPY1R 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.